NTRK1 and neoplasm: Although such events are exceedingly rare in iCCA, with a prevalence well below 1% [12], these alterations are clinically meaningful because TRK inhibitors can induce high ORRs across a broad range of solid tumors, leading to tumor-agnostic approvals based on fusion status alone (Fig. 2) [9].